NEUROCRINE BIOSCIENCES INC Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
NEUROCRINE BIOSCIENCES INC (NBIX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $2.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was -$3.40M.
- NEUROCRINE BIOSCIENCES INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $262.60M, a 31.96% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00.
- NEUROCRINE BIOSCIENCES INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $271.60M, a 35.26% increase from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $200.80M.
- NEUROCRINE BIOSCIENCES INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.60M 10-Q · filed 2026-07-31 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$3.40M derived: sum of 2 quarters · filed 2026-02-11 | $0.00 10-K · filed 2026-02-11 | |
| 2025-09-30 | -$3.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $0.00 10-Q · filed 2025-10-28 | ||
| 2025-06-30 | $3.40M 10-Q · filed 2026-07-31 | |||
| 2024-12-31 | $262.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $262.60M derived: sum of 2 quarters · filed 2026-02-11 | $271.60M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $9.00M 10-Q · filed 2025-10-28 | ||
| 2024-06-30 | $9.00M 10-Q · filed 2025-07-30 | |||
| 2023-12-31 | $199.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $199.00M derived: sum of 2 quarters · filed 2026-02-11 | $200.80M 10-K · filed 2026-02-11 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $1.80M 10-Q · filed 2024-10-30 | ||
| 2023-06-30 | $1.80M 10-Q · filed 2024-08-01 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $0.00 derived: sum of 2 quarters · filed 2025-02-10 | $0.00 derived: sum of 3 quarters · filed 2025-02-10 | $0.00 10-K · filed 2025-02-10 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $0.00 derived: sum of 2 quarters · filed 2023-10-31 | $0.00 10-Q · filed 2023-10-31 | $1.80M derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $0.00 10-Q · filed 2023-08-01 | $1.80M derived: sum of 3 quarters · filed 2024-02-09 | $1.80M derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-04 | $1.80M derived: sum of 2 quarters · filed 2024-02-09 | $1.80M derived: sum of 3 quarters · filed 2024-02-09 | $7.40M derived: sum of 4 quarters · filed 2024-02-09 |
| 2021-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $1.80M derived: sum of 2 quarters · filed 2024-02-09 | $7.40M derived: sum of 3 quarters · filed 2024-02-09 | $23.40M 10-K · filed 2024-02-09 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $5.60M derived: sum of 2 quarters · filed 2022-11-01 | $21.60M 10-Q · filed 2022-11-01 | $34.40M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-06-30 | $5.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $21.60M 10-Q · filed 2022-08-04 | $34.40M derived: sum of 3 quarters · filed 2023-02-09 | $34.40M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-03-31 | $16.00M 10-Q · filed 2022-05-04 | $28.80M derived: sum of 2 quarters · filed 2023-02-09 | $28.80M derived: sum of 3 quarters · filed 2023-02-09 | $28.80M derived: sum of 4 quarters · filed 2023-02-09 |
| 2020-12-31 | $12.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $12.80M derived: sum of 2 quarters · filed 2023-02-09 | $12.80M derived: sum of 3 quarters · filed 2023-02-09 | $12.80M 10-K · filed 2023-02-09 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $0.00 derived: sum of 2 quarters · filed 2021-11-01 | $0.00 10-Q · filed 2021-11-01 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $0.00 10-Q · filed 2021-08-03 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $77.10M 10-K · filed 2022-02-11 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |